Abstract:
Objective To evaluate the role of 16α-18Ffluoro-17β-oestradiol(18F-FES)PET/CT in the diagnosis and management of breast cancer.
Methods Nineteen pre-operation cases with breast cancer and 7 post-operation cases with metastatic breast cancer underwent 18F-FES PET/CT and 18F-FDG PET/CT, and comparative analysis with the expression of estrogen receptor(ER)was performed.
Results Of the primary lesions, the ER was positive in 9 patients(10 lesions), negative in 10 patients(11 lesions). The maximum standardized uptake value(SUVmax) for FES uptake was positively related to the lesion size and ER expression. The mean SUVmax for FES uptake was 3.45±2.34 in the 10 ER positive tumors, and 0.74±0.12 in the 11 ER negative tumors, which showed significant differences between the two groups(t=3.782, P < 0.01). The sensitivity, specificity and accuracy of FES PET for diagnosis ER positive patients were 100%, 90.90% and 95.23% respectively. Sixty-four 18F-FES positive metastases were found in the three ER positive metastatic patients, whereas only 47 18F-FDG positive metastases were found.
Conclusion 18F-FES PET/CT will be useful for diagnosis, individualized medicine and detecting therapeutic changes in patients with ER positive breast cancer.